Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious, and other diseases.

 
 
 
 

2017 News Releases

 
03/17/17 Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference
03/02/17 Sarepta Therapeutics to Present Company Overview at the Cowen and Company 37th Annual Health Care Conference
02/28/17Download PDFSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/28/17Download PDFSarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments
02/21/17 Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M
02/15/17 Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments on February 28, 2017
01/31/17Download PDFSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/17Download PDFSarepta Therapeutics Enters into License Agreement with Nationwide Children’s Hospital for Galgt2 Gene Therapy Program
01/10/17Download PDFSarepta Therapeutics Enters into Research Agreement and Option Agreement with Nationwide Children’s Hospital for Microdystrophin Gene Therapy Program
01/03/17Download PDFSarepta Therapeutics to Present Company Overview at the 2017 35th Annual J.P. Morgan Healthcare Conference



This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.